A Phase 3 interventional study of Octreotide Long Acting Release and Standard Treatment in Chemotherapy-induced Diarrhea, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-05-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Colorectal Neoplasms by Novartis — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Novartis.
Among the 30 studies in Colorectal Neoplasms by Novartis, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 8th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 30 studies in Colorectal Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Denmark, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Belgium, Canada and 7 more countries
Ages 18–100
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 123 across the 30 interventional studies. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Colorectal Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Colorectal Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
Eligible patients will have a diagnosis of colorectal cancer, and will be candidates to adjuvant chemotherapy or first-line chemotherapy for metastatic disease with a regimen containing fluorouracil, capecitabine and/or irinotecan. Eligible chemotherapy regimens include Irinotecan, Leucovorin (folinic acid), and Fluorouracil(IFL), Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI), combinations of Irinotecan and Capecitabine, the Roswell Park regimen and the Mayo Clinic regimen, all of them without or with Oxaliplatin, Bevacizumab or Cetuximab. Patients receiving Erlotinib, or other Tyrosine-kinase, Epidermal Growth Factor Receptor (EGFR)-inhibitors, will not be eligible.
The acute treatment for diarrhea will be left to physician's discretion in both groups. Patients in the control arm will be treated without Octreotide LAR. Patients in the experimental arm will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first. Patient evaluation will be done at each cycle for efficacy and toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevention of Chemotherapy Induced Diarrhea (CID)
Drug: Octreotide Long Acting Release
Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Other: Standard Treatment
Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
Also known as: Octreotide LAR, Sandostatin LAR
Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
Percentage of Participants Developing Diarrhea (Grade 1 to 4)
The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
Time frame: 6 month overall
Number of Episodes of Diarrhea by Patient
Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis.
Time frame: 6 months overall
Number of Episodes of Diarrhea by Patient by Cycle
Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.)
Time frame: at each cycle (28 days per cycle)
Percentage of Patients by Grade of Diarrhea
Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
Time frame: 6 months overall
Percentage of Episodes by Grade
Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
Time frame: 6 months overall
Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea
For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered.
Time frame: 6 months overall
Percentage of Participants Who Need Opioids for Control of Diarrhea
Time frame: 6 months overall
Percentage of Patients Hospitalized Due to Diarrhea
Time frame: 6 months overall
Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea
Time frame: 6 months overall
Percentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)
Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as \> 20 mm with conventional techniques (CT, MRI) or as \> 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.
Time frame: Day 56, Day 84, Day 112, Day 140, Day 168
Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)
Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point.
Time frame: Baseline to Day 168
| Milestone | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Started | 68 | 71 |
| Completed | 48 | 58 |
| Not completed | 20 | 13 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Protocol violation | 6 | 2 |
| Withdrew: Death | 4 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Disease progression | 2 | 2 |
| Withdrew: Use of illicit drugs | 1 | 0 |
The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
| Percentage of Participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Percentage of Participants Developing Diarrhea (Grade 1 to 4) | 76.1 (64.7 to 84.7) | 78.9 (68 to 86.8) |
Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis.
| Episodes/patients/day | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Number of Episodes of Diarrhea by Patient | 21.6 ± 24.3 | 20.4 ± 19.6 |
Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.)
| Episodes/patient/cycle | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Cycle 1 (n=20, 18) | 2.6 ± 2.2 | 2.2 ± 2 |
| Cycle 2 (n=36,38) | 8.2 ± 6.8 | 5.9 ± 6.2 |
| Cycle 3 (n=33,39) | 6.9 ± 7.8 | 6.7 ± 6.5 |
| Cycle 4 (n=24, 27) | 8.6 ± 7.1 | 7.1 ± 7.1 |
| Cycle 5 (n=20,29) | 8.1 ± 7.1 | 7 ± 8.8 |
| Cycle 6 (n=22, 22) | 6.1 ± 6.9 | 5.8 ± 5.3 |
| Cycle 7 (n= 16, 20) | 4.8 ± 6.3 | 6.6 ± 6.4 |
Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
| Percentage of Participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Grade 1 | 41.2 | 26.8 |
| Grade 2 | 25.5 | 51.8 |
| Grade 3 | 33.3 | 21.4 |
| Grade 4 | 0 | 0 |
Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.
| Percentage of Episodes | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Grade 1 | 65.4 | 66.9 |
| Grade 2 | 23.3 | 27.2 |
| Grade 3 | 11.3 | 5.9 |
| Grade 4 | 0 | 0 |
For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered.
| Percentage of participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea | 26.9 (17.7 to 38.5) | 11.3 (5.8 to 20.7) |
| Percentage of Participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Percentage of Participants Who Need Opioids for Control of Diarrhea | 1.5 (0.3 to 8.0) | 1.4 (0.2 to 7.6) |
| Percentage of patients | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Percentage of Patients Hospitalized Due to Diarrhea | 6 | 4.2 |
| Percentage of Participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea | 4.5 (1.5 to 12.4) | 7.0 (3.0 to 15.4) |
Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as \> 20 mm with conventional techniques (CT, MRI) or as \> 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.
| Percentage of Participants | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Day 56 (N=11,2) | 45.5 (21.3 to 72.0) | 0.0 (0.0 to 65.8) |
| Day 84 (N=5,3) | 60.0 (23.1 to 88.2) | 100 (43.8 to 100) |
| Day 112 (N=1,1) | 100 (20.7 to 100) | 0.0 (0.0 to 79.3) |
| Day 140 (N=9,1) | 44.4 (18.9 to 73.3) | 100 (20.7 to 100) |
| Day 168 (N=2,1) | 100 (34.2 to 100) | 100 (20.7 to 100) |
Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point.
| Units on a scale | Octreotide Long Acting Release | Standard Treatment |
|---|---|---|
| Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) | 0.5 ± 1.9 | 3.4 ± 2.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide LAR | — | 15/68 (22.1%) | 63/68 (92.6%) |
| Standard Treatment | — | 14/71 (19.7%) | 68/71 (95.8%) |
| Event | Octreotide LAR | Standard Treatment |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/68 | 4/71 |
| AnaemiaBlood and lymphatic system disorders | 2/68 | 0/71 |
| Gastrointestinal obstructGastrointestinal disorders | 2/68 | 2/71 |
| MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/68 | 0/71 |
| PyelonephritisInfections and infestations | 0/68 | 2/71 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/68 | 2/71 |
| NauseaGastrointestinal disorders | 1/68 | 0/71 |
| Mucosal inflammationGeneral disorders | 1/68 | 0/71 |
| GastroenteritisInfections and infestations | 1/68 | 0/71 |
| International normalisedInvestigations | 1/68 | 0/71 |
| Event | Octreotide LAR | Standard Treatment |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 54/68 | 56/71 |
| NauseaGastrointestinal disorders | 33/68 | 46/71 |
| Abdominal painGastrointestinal disorders | 19/68 | 23/71 |
| Neuropathy peripheralNervous system disorders | 18/68 | 21/71 |
| VomitingGastrointestinal disorders | 20/68 | 16/71 |
| MucositisGeneral disorders | 12/68 | 20/71 |
| Decreased appetiteMetabolism and nutrition disorders | 17/68 | 14/71 |
| NeutropeniaBlood and lymphatic system disorders | 11/68 | 17/71 |
| AnaemiaBlood and lymphatic system disorders | 15/68 | 11/71 |
| AstheniaGeneral disorders | 11/68 | 12/71 |
| Age, Continuous(years) | Octreotide Long Acting Release | Standard Treatment | Total |
|---|---|---|---|
| Mean | 56.2 ± 12.8 | 55.5 ± 11.4 | 55.85 ± 12.1 |
| Sex: Female, Male(Participants) | Octreotide Long Acting Release | Standard Treatment | Total |
|---|---|---|---|
| Female | 37 | 41 | 78 |
| Male | 31 | 30 | 61 |
The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide